Neonatal Treatment with Beta-cell Stimulatory Agents Reduces Diabetes in BB Rats
Author Information
Author(s): KARSTEN BUSCHARD, TROELS BOCK, CHARLOTTE R. PEDERSEN, SUSANNE V. HANSEN, KIM AAEN, MERETE JORGENSEN, MICHAEL WOLLIKE HANSEN, TROELS W. KJAER, IDA HAGEMAN, KNUD JOSEFSEN
Primary Institution: Bartholin Instituttet, Kommunehospitalet, DK-1399 Copenhagen K, Denmark
Hypothesis
Does neonatal treatment with beta-cell stimulatory drugs influence the incidence of diabetes in BB rats?
Conclusion
Neonatal treatment with various beta-cell stimulatory agents reduces diabetes incidence in BB rats.
Supporting Evidence
- Diabetes incidence in control BB rats was 63.8%.
- Experimental BB rats treated with arginine-glucose had a diabetes incidence of 47%.
- Glucagon treatment resulted in a 37% diabetes incidence.
- Tolbutamide-glucose treatment led to a 36% diabetes incidence.
- Theophylline-glucose treatment resulted in a 39% diabetes incidence.
- Long-term arginine-glucose treatment did not show superior results compared to neonatal treatment.
Takeaway
Giving special medicine to baby rats can help them not get diabetes when they grow up.
Methodology
Newborn BB rats were treated with beta-cell stimulatory agents and observed for diabetes development over 200 days.
Limitations
The study was conducted on BB rats, which may not fully represent human diabetes.
Participant Demographics
BB rats, both male and female, with a focus on neonatal treatment.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website